natgillin/translations-raw huggingface dataset:
Daronrix er en hvid, let mælkeagtig væske og kommer i en fyldt sprøjte (0,5 ml) med 1 dosis i pakningsstørrelser på 1 og 10 med eller uden kanyler.
Daronrix is a white, slightly milky liquid and is presented in a pre-filled syringe (0.5 ml) for 1 dose in pack sizes of 1 and 10 with or without needles
SÅDAN OPBEVARER DU DARONRIX
HOW TO STORE DARONRIX
Det er usandsynligt, at der vil komme bivirkninger, som skulle gøre dig ude af stand til at køre bil eller anvende maskiner.
After administration of Daronrix, it is unlikely that side effects would unable you to drive or use machines.
5 ml i ampul (type I-glas) til 10 doser - pakningsstørrelse på 50
5 ml in ampoule (type I glass) for 10 doses - pack size of 50
Dette produkt indeholder et konserveringsmiddel kaldet Thiomersal , og du kan derfor få en allergisk reaktion.
Important information about some of the ingredients of Daronrix Thiomersal (preservative) is present in this product, and it is possible that you may experience an allergic reaction.
Som en konsekvens heraf skal indehaveren af markedsføringstilladelsen indsende regelmæssige PSUR på nedennævnte tidspunkter og i nedenfor anførte format, så snart pandemien er erklæret (fase 6 i WHO's beredskabsplan for verdensomspændende influenza) og pandemivaccinen anvendt.
In consequence, as soon as the pandemic is declared (Phase 6 of the WHO global Influenza preparedness plan) and the pandemic vaccine is used, the MAH shall submit periodic safety update reports with periodicity and format defined as follows:
Tag ikke Daronrix:
Daronrix should not be given:
♦ Meget sjælden (forekommer hos færre end 1 ud af 10.000 patienter):
♦ Very rare (less than 1 per 10,000 doses of vaccine):
INDHOLDSMÆNGDE ANGIVET SOM VÆGT, VOLUMEN ELLER ANTAL DOSER 10 doser (5 ml)
CONTENTS BY WEIGHT, BY VOLUME OR BY UNIT 10 doses (5 ml)
• hvis du tidligere har haft en allergisk reaktion mod Daronrix eller et af indholdsstofferne (inkl.
• if you have previously had any allergic reaction to Daronrix, or any ingredient (including eggs, chicken protein, gentamicin sulphate (antibiotic)) contained in this vaccine.
♦ Meget almindelig (forekommer hos flere end 1 ud af 10 patienter):
♦ Very common (more than 1 per 10 doses of vaccine):
Data fra mockup-vaccinationer støtter den vaccinationsstrategi, der sandsynligvis vil blive anvendt med den pandemiske vaccine.
Data obtained with the mock-up vaccine will support a vaccination strategy that is likely to be used for the pandemic vaccine: clinical immunogenicity, safety and reactogenicity data obtained with mock-up vaccines are relevant for the pandemic vaccines.
Neuralgi, paræstesi, konvulsioner, forbigående trombocytopeni Der er indberettet allergiske reaktioner, som i sjældne tilfælde kan føre til chok.
Allergic reactions, in rare cases leading to shock, have been reported.
- Spørg lægen eller på apoteket, hvis der er mere, du vil vide.
- If you have any further questions, ask your doctor or pharmacist.
MARKEDSFØRINGSTILLADELSEN
Marketing Authorisation Holder
OPLYSNINGER, DER SKAL ANFØRES PÅ DEN YDRE EMBALLAGE ENKELTDOSISBEHOLDER
PARTICULARS TO APPEAR ON THE OUTER PACKAGING MONODOSE PRESENTATION
Pandemisk influenzavaccine bør anvendes i overensstemmelse med officielle retningslinjer (se afsnit 4.2 og 5.1).
Pandemic influenza vaccine should be used in accordance with official guidance.
50 x 10 doser 1 dosis (0,5 ml)
50 x 10 doses 1 dose (0.5 ml)
10 x 1 dosis 1 dosis (0,5 ml)
10 x 1 dose 1 dose (0.5 ml)
DET SKAL DU VIDE, FØR DU BEGYNDER AT BRUGE DARONRIX
BEFORE YOU RECEIVE DARONRIX
Hætteglas 50 x 20 doser 1 dosis (0,5 ml)
50 x 20 doses 1 dose (0.5 ml)
5 ml i hætteglas (type I-glas) til 10 doser - pakningsstørrelse på 50 10 ml i hætteglas (type I-glas) til 20 doser - pakningsstørrelse på 50
10 ml in vial (type I glass) for 20 doses - pack size of 50
FLERDOSISBEHOLDER HÆTTEGLAS (10 DOSER) X 50 HÆTTEGLAS (20 DOSER) X 50 AMPUL (10 DOSER) X 50
AMPOULE (10 DOSES) X 50
LÆGEMIDDELFORM Injektionsvæske, suspension Uklar, hvis suspension.
PHARMACEUTICAL FORM Suspension for injection.
Ampul
Vial
LÆGEMIDDELFORM Injektionsvæske, suspension Uklar, hvid suspension.
Turbid white suspension.
♦ Almindelig (forekommer hos mellem 1 og 10 ud af 100 patienter):
♦ Common (less than 1 per 10 but more than 1 per 100 doses of vaccine):
Spørg din læge eller apoteket til råds, før du tager nogen form for medicin.
please tell your doctor or pharmacist.
Daronrix, injektionsvæske, suspension Pandemisk influenzavaccine (hele virion, inaktiveret, adjuveret)
Daronrix, suspension for injection in pre-filled syringe Pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
♦ Ikke almindelig (forekommer hos mellem 1 og 10 ud af 1.000 patienter):
♦ Uncommon (less than 1 per 100 but more than 1 per 1000 doses of vaccine):
Daronrix, injektionsvæske, suspension, flerdosisbeholder Pandemisk influenzavaccine (hele virion, inaktiveret, adjuveret)
Daronrix, suspension for injection in multidose container Pandemic influenza vaccine (whole virion, inactivated, adjuvanted)
Alle hjælpestoffer er anført under punkt 6.1.
For a full list of excipients see section 6.1.
Ikke almindelig (≥ 1/1.000, < 1/100) Generaliserede hudreaktioner inkl.
Uncommon (≥1/1,000 to <1/100): Generalised skin reactions including pruritus, urticaria or non-specific rash.
♦ Sjælden (forekommer hos mellem 1 og 10 ud af 10.0000 patienter):
♦ Rare (less than 1 per 1000 but more than 1 per 10,000 doses of vaccine):
• Øget svedproduktion, blå mærker
• Increased sweating, bruising
Et af de aktive stoffer, palonosetron, har selvstændigt været godkendt i EU siden 2005.
One of the active substances, palonosetron, has been authorised on its own in the EU since 2005.
Europa-Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Akynzeo den 27. maj 2015.
The European Commission granted a marketing authorisation valid throughout the European Union for Akynzeo on 27 May 2015
Patienten tager én kapsel en time før start af hver kemoterapicyklus.
The patient takes one capsule one hour before starting each chemotherapy cycle.
Akynzeo netupitant/palonosetronhydrochlorid
Akynzeo netupitant / palonosetron hydrochloride
Dette dokument er et sammendrag af den europæiske offentlige vurderingsrapport (EPAR) for Akynzeo.
This is a summary of the European public assessment report (EPAR) for Akynzeo.
Den fuldstændige EPAR og resuméet af risikostyringsplanen for Akynzeo findes på agenturets websted under: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
The full EPAR and risk management plan summary for Akynzeo can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Udvalget konkluderede derfor, at fordelene ved lægemidlet opvejer risiciene, og anbefalede, at det godkendes til anvendelse i EU.
The Committee therefore concluded that the medicine's benefits are greater than its risk and recommended that it be approved for use in the EU.
Der er udarbejdet en risikostyringsplan for at sikre, at Akynzeo anvendes så sikkert som muligt.
A risk management plan has been developed to ensure that Akynzeo is used as safely as possible.
Tallene for dag 2 til dag 5 var 77 % for patienter i Akynzeo-gruppen og 70 % for patienter i palonosetron-gruppen.
The figures for day 2 to day 5 were 77% for patients in the Akynzeo group and 70% for those in the palonosetron group.
Andre oplysninger om Akynzeo
Other information about Akynzeo
Denne undersøgelse involverede 1455 patienter, og patienterne tog som en ekstra behandling dexamethason, et andet lægemiddel, der anvendes til at forhindre opkastning.
This study involved 1,455 patients and the patients took dexamethasone, another medicine used to prevent vomiting, as an additional treatment.
De hyppigste bivirkninger, der er indberettet med Akynzeo, er hovedpine (set hos 3,6 % af patienterne), forstoppelse (3,0 %) og træthed (1,2 %).
The most common side effects reported with Akynzeo are headache (seen in 3.6% of patients), constipation (3.0%) and fatigue (1.2%).
Akynzeo fås som kapsler, der indeholder 300 mg netupitant og 0,5 mg palonosetron.
Akynzeo is available as capsules containing 300 mg of netupitant and 0.5 mg of palonosetron.
Hvilke foranstaltninger træffes der for at sikre risikofri og effektiv anvendelse af Akynzeo?
What measures are being taken to ensure the safe and effective use of Akynzeo?
Cirka 88 % af de patienter, der tog Akynzeo, oplevede ingen opkastning på dag 1 efter den første kemoterapicyklus, sammenlignet med 85 % af patienter, der tog palonosetron.
Around 88% of patients taking Akynzeo experienced no vomiting on day 1 following the first chemotherapy cycle, compared with 85% of patients taking palonosetron.
På baggrund af denne er der anført sikkerhedsoplysninger i produktresuméet og indlægssedlen for Akynzeo, herunder passende forholdsregler, som patienter og sundhedspersonale skal følge.
Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Akynzeo, including the appropriate precautions to be followed by healthcare professionals and patients.
Agenturets Udvalg for Lægemidler til Mennesker (CHMP) fremhævede, at Akynzeo var effektivt til at forhindre både de umiddelbare og forsinkede faser af kvalme og opkastning efter kemoterapi, og at lægemidlet har en gunstig sikkerhedsprofil.
The Agency's Committee for Medicinal Products for Human Use (CHMP) noted that Akynzeo was effective at preventing both the immediate and delayed phases of nausea and vomiting following chemotherapy, and that the medicine has a favourable safety profile.
En anden større undersøgelse så på fordelene ved Akynzeo hos patienter, der gennemgik moderat emetogen kemoterapi.
A second main study looked at the benefits of Akynzeo in patients undergoing moderately emetogenic chemotherapy.
Akynzeo indeholder de aktive stoffer netupitant og palonosetron.
Akynzeo contains the active substances netupitant and palonosetron.
I en større undersøgelse, der sammenlignede Akynzeo med palonosetron alene, oplevede 90 % af de patienter, der tog Akynzeo (121 ud af 135), ingen opkastning inden for 5 dage fra påbegyndelse af højemetogen kemoterapi, sammenlignet med 77 % af de patienter, der tog palonosetron alene (104 ud af 136).
In a main study comparing Akynzeo with palonosetron alone, 90% of patients taking Akynzeo (121 out of 135) experienced no vomiting within 5 days of starting highly emetogenic chemotherapy compared with 77% of patients taking palonosetron alone (104 out of 136).
Hvorfor blev Akynzeo godkendt?
Why is Akynzeo approved?
Hvis du ønsker yderligere oplysninger om behandling med Akynzeo, kan du læse indlægssedlen (også en del af denne EPAR) eller kontakte din læge eller dit apotek.
For more information about treatment with Akynzeo, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Det er ikke en praktisk vejledning i, hvordan Akynzeo bør anvendes.
It is not intended to provide practical advice on how to use Akynzeo.
Hvad er Akynzeo, og hvad anvendes det til?
What is Akynzeo and what is it used for?
Hvilke risici er der forbundet med Akynzeo?
What are the risks associated with Akynzeo?
Nogle kemoterapier er kendt for at give svær kvalme og opkastning, og Akynzeo anvendes hos patienter, der enten får kemoterapi, der er kraftigt kvalmefremkaldende (emetogen) baseret på cancerlægemidlet cisplatin eller andre kemoterapier, der er moderat emetogene.
Some chemotherapy is known to induce severe nausea and vomiting, and Akynzeo is used in patients receiving either highly emetogenic (vomit-inducing) chemotherapy based on the cancer medicine cisplatin, or other chemotherapies that are moderately emetogenic.
De to aktive stoffer i Akynzeo virker ved at blokere to forskellige mekanismer, der medvirker til at fremkalde kvalme og opkastning under kemoterapi.
The two active substances in Akynzeo work by blocking two different mechanisms involved in inducing nausea and vomiting during chemotherapy.
Akynzeo er et lægemiddel, der anvendes til at forebygge kvalme og opkastning hos voksne patienter med cancer, som modtager kemoterapi (lægemidler til behandling af cancer).
Akynzeo is a medicine used to prevent nausea (feeling sick) and vomiting in adult patients with cancer who are receiving chemotherapy (medicines to treat cancer).
Hvis du ønsker praktisk vejledning om anvendelsen af Akynzeo, kan du læse indlægssedlen eller kontakte din læge eller dit apotek.
For practical information about using Akynzeo, patients should read the package leaflet or contact their doctor or pharmacist.
Ved at anvende begge aktive stoffer sammen hjælper Akynzeo med til at tilvejebringe kontrol af både de umiddelbare og forsinkede faser af kvalme og opkastning, der indtræffer efter kemoterapi.
By having both active substances together, Akynzeo helps provide control for both the immediate and delayed phases of nausea and vomiting than occur following chemotherapy.
Hvordan anvendes Akynzeo?
How is Akynzeo used?
Palonosetron blokerer på den anden side 5HT3-receptorerne i tarmsystemet, som er ansvarlige for den umiddelbare fase (der indtræffer inden for de første 24 timer).
receptors, which are found in the nervous system and are responsible for the delayed phase of nausea and vomiting (that occurs after the first 24 hours); palonosetron, on the other hand, blocks 5HT3 receptors in the gut, which are responsible for the immediate phase (that occurs within the first 24 hours).
Hvilke fordele viser undersøgelserne, at der er ved Akynzeo?
What benefits of Akynzeo have been shown in studies?
Hvordan virker Akynzeo?
How does Akynzeo work?
Netupitant virker ved at blokere neurokinin-1(NK1)-receptorerne, som findes i nervesystemet, og som er ansvarlige for den forsinkede kvalme- og opkastningsfase (der indtræffer efter de første 24 timer).
Netupitant works by blocking neurokinin-1 (NK1)
MF (EU)-nummer (Særnavn) Navn
MA (EU) number (Invented) name Strength Pharmaceutical Form Route of Administra
BILAG I Fortegnelse over lægemidlernes navne, lægemiddelformer, styrker, indgivelsesveje, indehavere af markedsføringstilladelser i medlemsstaterne
Annex I List of the names, pharmaceutical forms, strengths of the medicinal products, routes of administration, marketing authorisation holders in the member states
Kruczkowskiego 8 00-380 Warszawa Poland
Kruczkowskiego 8 00-380 Warzawa Poland
Beriplast og tilhørende navne Medlemsstat (i EØS)
Beriplast and associated names Member State (in EEA)
Artiss og tilhørende navne; Tisseel og tilhørende navne; Tissucol og tilhørende navne Medlemsstat (i EØS)
Artiss and associated names; Tisseel and associated names; Tissucol and associated names Member State (in EEA)
Aprotinin 15000 KIE;
Aprotinin 15000 KIU;
1221 Vienna
A- 1221 Vienna Austria
Storbritannien Baxter Healthcare Limited, Caxton Way,
United Kingdom Baxter Healthcare Limited, Caxton Way,
Luxembourg Baxter AG Industriestraße 67
The Netherlands Baxter AG Industriestraße 67
P 0,5 ml, 1 ml, 3 ml, powders and solvents for sealant
BERIPLAST P 0.5 ml, 1 ml, 3 ml, powders and solvents for sealant Combi-Set
Grækenland CSL BEHRING 5 Hadjiyianni Mexi str, 11528-Athens
CSL BEHRING 5 Hadjiyianni Mexi str, 11528-Athens Greece
Zona Industrial da Abrunheira - Edifício 10Sintra Business Park 2710-089 Sintra Portugal
Zona Industrial da Abrunheira - Edifício 10 - Sintra Business Park
Protein i alt 200-260 mg;
Total Protein 200-260 mg;
Protein i alt 500-650 mg;
Total Protein 500-650 mg;
Humant fibrinogen (koagulerbart protein): 72-110 mg/ml
Human fibrinogen (clottable protein): 72-110 mg/ml
Calciumchlorid: 40 µmol/ml
Calcium chloride: 40 µmol/ml
Flaske 3: Humant thrombin 500 IE/ml;
Bottle 3: Human Thrombin 500 IU/ml;
Faktor XIII 10-50 IE;
Factor XIII 30 a.e
Komponent 1
Component 1
Komponent 2
Component 2
2. komponent: Thrombin 500 IE/ml
2nd Component: Thrombin 500 UI/ml
BAXTER, S.L.Polígono Industrial Sector 14 Pouet de Camilo, 2 46394 Ribarroja del Turia Valencia
Polígono Industrial Sector 14 Pouet de Camilo, 2
Thrombin 1000 IE eller Thrombin 8 IE; Calciumchloriddihydrat 11,76 mg
Thrombin 1000 IU or Thrombin 8 UI; Calcium Chlorid Dihydrate 11.76 mg
Combi-Set 0,5ml/1ml/3m l
Beriplast P CombiSet 0,5ml/1ml/3ml
Thrombin 2500 IE eller Thrombin 20 IE; Calciumchloriddihydrat 29,4 mg
Thrombin 2500 IU or Thrombin 20 UI; Calcium Chlorid Dihydrate 29.4 mg
Calciumchlorid: 40 µmol/ml Faktor XIII: ≤10 IE/ml
Calcium chloride: 40 µmol/ml Factor XIII: 30 IU/ml
Komponent 1:
Component 1:
Koagulerbart protein: 150-230 mg, hvoraf fibrinogen 140-220 mg; Plasmafibronectin 4-18 mg;
Clottable protein: 150-230 mg, thereof Fibrinogen 140-220 mg; Plasma Fibronectin 4-18 mg; Factor XIII 20-100 UI;
Fibrinogen, humant 90,00 mg/ml Faktor XIII: 10,00 IE/ml Fibronectin: 5,50 mg/ml Plasminogen: 0,08 mg/ml Aprotinin 3000,0 KIE***/ml
Fibrinogen human 90,00 mg /ml Factor XIII : 10,00 UI/ml Fibronectin : 5,50 mg/ml Plasminogen : 0,08 mg/ml Aprotinin 3000,0 UIK*** /ml
Koagulerbart protein: 375-575 mg, hvoraf fibrinogen 350-550 mg; Plasmafibronectin 10-45 mg;
Clottable protein: 375-575 mg, thereof Fibrinogen 350-550 mg; Plasma Fibronectin 10-45 mg; Factor XIII 50-250 UI;
Thrombin S lyofiliseret: 500 IE/ml Thrombin L lyofiliseret: 4 IE/ml Calciumchlorid: 5,88 mg/ml
Thrombin S lyophilized: 500 I.E/ml Thrombin L lyophilized: 4 I.E/ml Calcium chloride: 5,88 mg/ml
1. komponent:
1st Component:
Komponent 2:
Component 2:
Thrombin 500 IE eller Thrombin 4 IE; Calciumchloriddihydrat 5,88 mg
Thrombin 500 IU or Thrombin 4 UI; Calcium Chlorid Dihydrate 5.88 mg
Kutan anvendelse
Cutaneous Use
Thrombin (humant) 500 IE/ml Calciumchlorid: 5,88 mg/ml
Thrombin (human) 500 I.E./ml Calcium chloride: 5,88 mg/ml
Proteiner 50 mg/ml; Flaske 4: Humant thrombin 4 IE/ml; Proteiner 50 mg/ml; Flaske 5: calciumchlorid 40 µmol/ml
Proteins 50mg/ml; Bottle 4: Human Thrombin 4 UI/ml; Proteins 50mg/ml;
Grækenland BAXTER HELLAS LTD 3 Metsovou str,
BAXTER HELLAS LTD 3 Metsovou str, 14121-N Irakleio, Athens
2. komponent:
2nd Component:
Pulver, opløsning og solvens til vævsklæber
Powder, solution and solvent for sealant
Human fibrinogen: 90 mg Koagulationsfaktor XIII: 60 UI Aprotinin: 1000 KUI Trombin: 7,6 mg Calcium chloride: 5,9 mg
Human fibrinogen: 90 mg Coagulation factor XIII: 60 UI Aprotinin: 1000 KUI Trombin: 7,6 mg Calcium chloride: 5,9 mg
Fibrinogen: 72-110 mg/ml Aprotinin: 3000 KIE/ml Thrombin: 500 IE/ml i 45-55 mg protein i alt
Fibrinogen: 72-110mg/ml Aprotinin: 3000KIU/ml Thrombin: 500 IU/ml in 45-55mg total protein
Flaske 1: Proteiner i alt 100-130 mg/ml; koagulerbart protein 75-115 mg/ml, Faktor XIII 10-50 IE/ml; Plasminogen 0,04-0,12 mg/ml; Flaske 2: Bovint aprotinin 3000 KIE/ml (1,67 PEU/ml);
Bottle 1: Total Proteins 100-130 mg/ml; dont clottable protein 75-115 mg/ml, Factor XIII 10-50 UI/ml; Plasminogen 0.04-0.12 mg/ml; Bottle 2: Aprotinin bovine 3000 UIK/ml (1.67 UPE/ml);
Sprøjte TISSUCOL-APROTININ: Proteiner i alt 100-130 mg/ml; koagulerbart protein 75-115 mg/ml, heraf fibrinogen 70-110 mg/ml og plasmafibronectin 2-9 mg/ml; Faktor XIII 10-50 IE/ml; Plasminogen 0,040,12 mg/ml; Aprotinin 3000 KIE/ml (1,67 PEU/ml); Sprøjte THROMBINCALCIUMCHLORID: Proteiner 50 mg/ml; Thrombin 500 IE/ml; calciumchlorid 40 µmol/ml
Syringe TISSUCOL-APROTININ: Total Proteins 100-130 mg/ml; clottable protein 75-115 mg/ml, of which fibrinogen 70-110 mg/ml and plasmatic fibronectin 2-9 mg/ml: Factor XIII 10-50 UI/ml; Plasminogen 0.04-0.12 mg/ml; Aprotinin 3000 UIK/ml (1.67 UPE/ml); Syringe THROMBIN-CALCIUM CHLORIDE: Proteins 50mg/ml; Thrombin 500 UI/ml; calcium chloride 40 µmol/ml
Fibrinogen: 70-110 mg/ml Plasmafibronectin (CIG): 2-9 mg/ml Faktor XIII: 10-50 E/ml Plasminogen: 0,04-0,12 mg/ml
Fibrinogen: 70-110mg/ml Plasmafibronectin (CIG): 2-9mg/ml Factor XIII: 10-50 U/ml Plasminogen: 0.04 - 0.12mg/ml
Combi-Set 1: fibrinogen: 90 mg/ml Koagulationsfaktor XIII: 60 U/ml aprotinin: 1000 KIU/ml = 0,56 PEU/ml
Combi-Set 1: fibrinogen: 90 mg/ml coagulation factor XIII: 60 U/ml aprotinin: 1000 KIU/ml=0.56 PEU/ml
Plasminogen 0,08-0,24 mg;
Plasminogen 0.08-0.24 mg; Aprotinin 6000 KIU;
Faktor XIII ≤10 IE/ml Aprotinin: 3000 KIE/ml Humant thrombin: 500 IE/ml Calciumchlorid: 40 μmol/ml
Factor XIII ≤ 10 UI/ml Aprotinin: 3000 UIK/ml Human Thrombin: 500 UI/ml Calcium chloride: 40 μmol/ml
Plasminogen 0,04-0,12 mg;
UI/ml; Plasminogen 0.04-0.12 mg/ml;
Fibrinogen: 90 mg/ml Koagulationsfaktor XIII: 60 U/ml Aprotinin: 1000 KIU/ml = 0,56 PEU/ml
Fibrinogen: 90 mg/ml Coagulation factor XIII: 60 U/ml Aprotinin: 1000 KIU/ml=0.56 PEU/ml
Koagulerbart protein: 75-115 mg, hvoraf fibrinogen 70-110 mg; Plasmafibronectin 2-9 mg;
Total Protein 100-130 mg; Clottable protein: 75-115 mg, thereof Fibrinogen 70-110 mg; Plasma Fibronectin 2-9 mg; Factor XIII 10-50 UI;
Humant fibrinogen (72-110 mg/ml) Faktor xiii (≤10 IE) Aprotinin (3000 KIE2/ml) Humant thrombin (500 IE3/ml) Calciumchlorid (40 mikromol/ml)
Human fibrinogen (72-110 mg/ml) Factor xiii (≤10 UI) Aprotinin (3000 KUI2/ml) Human thrombin (500 UI3/ml) Calcium chloride (40micromol/ml)
Human fibrinogen: 90 mg/ml Koagulationsfaktor XIII: 60 e/ml Aprotinin: 1000 EIK/ml Thrombin: 7,6 mg/ml Calcium chloride: 5,9 mg/ml
Human fibrinogen: 90 mg/ml Coagulation factor XIII: 60 e/ml Aprotinin: 1000 EIK/ml Thrombin: 7,6 mg/ml Calcium chloride: 5,9 mg/ml
Humant fibrinogen 91 mg/ml Human faktor XIII 10 IE/ml Bovint aprotinin 3000 KIE/ml Humant thrombin 500 IE/ml Calciumchlorid (40 mikromol/ml)
Human Fibrinogen 91 gm/ml Human Factor XIII 10 IU/ml Bovine Aprotinin 3000 IU/ml Human Thrombin 500 IU/ml Calcium Chloride 40 micromol/ml
enhed/ml Koagulationsfaktor XIII 30 mg/ml Plasminogen 80 μg/ml Thrombin, humant 500 IE/ml Plasmaprotein, humant 50 mg/ml Calciumchloriddihydrat 40 μg/ml
Aprotinin 3000KIE/ml Coagulation Factor XIII 30IE/ml Plasminogen 80 μg/ml Thrombin human 500 IE/ml Calcium Chloride Dihydrate 40 μg/ml
Humant fibrinogen 72-110 mg/ml Aprotinin 3000 KIE/ml Humant thrombin 500 IE/ml Calciumchlorid 40 µmol/ml
Human fibrinogen 72-110 mg/ml Aprotinin 3000 KIU/ml Human Thrombin 500 IU/ml Calcium Chloride 40 µmol/ml
Fibrinogen: 90 mg/ml Aprotinin (bovint): 1000 KIU/ml Thrombin: 500 IU/ml Calcium chloride: 5,9 mg/ml Koagulationsfaktor XIII: 60 U/ml
Fibrinogen: 90 mg/ml Aprotinin (bovine): 1000 KIU/ml Thrombin: 500 IU/ml Calcium chloride: 5,9 mg/ml Factor XIII: 60 U/ml
Fibrinogen: 70-110 mg/ml Koagulationsfaktor XIII: 10-50 IE/ml Plasmafibronectin: 2-9 mg/ml Aprotinin (bovint): 3000 KIE/ml
Fibrinogen:70-110 mg/ml Coagulation factor XIII: 10-50 I.E./ml Plasmafibronectin: 2-9 mg/ml Aprotinin (bovin): 3000 KIE/ml
Humant fibrinogen 91 mg/ml Aprotinin 3000 KIE/ml Humant thrombin 4 IE/ml Calciumchlorid 40 µmol/ml
Human fibrinogen 91 mg/ml Aprotinin 3000 KIU/ml Human Thrombin 4 IU/ml Calcium Chloride 40 µmol/ml
Topisk
Sealant
Fibrinogen: 70-110 mg/ml Plasmafibronectin: 2-9 mg/ml Koagulationsfaktor XIII: 10-50 IE/ml Aprotininopløsning: 3000 KIE/ml
Fibrinogen: 70 - 110 mg/ml Plasmafibronectin: 2 - 9 mg/ml Coagulation factor XIII: 10 - 50 I.E/ml Aprotininsolution: 3000 KIE/ml
Fibrinogen: 70-110 mg/ml Fibronectin: 2-9 mg/ml Thrombin: 500 IE/ml Calciumchlorid: 40 µmol/ml Faktor XIII: 10-50 IE/ml Aprotinin (bovint): 3000 KIE/ml
Fibrinogen: 70 - 110 mg/ml Fibronectine 2 - 9 mg/ml Thrombin: 500 IU/ml Calcium chloride: 40 µmol/ml Factor XIII: 10-50 IU/ml Aprotinine (bovine): 3000 KIU/ml
Fibrinogen: 90 mg/ml Koagulationsfaktor XIII: 60 U/ml Aprotinin: 1000 KIU = 0,56 EPU Thrombin: 500 IU/ml Calciumchloriddihydrat : 5,9 mg/ml
Fibrinogen: 90 mg/ml Coagulation factor XIII: 60 U/ml Aprotinin: 1000 KIU = 0,56 EPU Thrombin: 500 IU /ml Calcium chloride (dihydrate): 5,9 mg/ml
Humant fibrinogen: 72-110 mg/ml Faktor xiii: ≤10 IE Aprotinin: 3000 KIE2/ml Humant thrombin: 500 IE3/ml Calciumchlorid: 40 micromol/ml
Human fibrinogen: 72-110 mg/ml Factor xiii: ≤10 UI Aprotinin: 3000 KU12/ml Human thrombin: 500 UI3/ml Calcium chloride: 40 micromol/ml
Humant fibrinogen: 72-110 mg/ml Aprotinin: 3000 KIE/ml Humant thrombin: 4 IE/ml Calciumchlorid: 40 μmol/ml
Human Fibrinogen: 72-110 mg/ml Aprotinin: 3000 KIU/ml Human Thrombin: 4 IU/ml Calcium Chloride: 40 μmol/ml
Humant fibrinogen: 91 mg1/ml Aprotinin: 3000 KIE2/ml Humant thrombin: 500 IE3/ml Calciumchlorid: 40 µmol/ml
Human Fibrinogen: 91 mg1/ml Aprotinin: 3000 KIU2/ml Human Thrombin: 500 IU3/ml Calcium Chloride: 40 µmol/ml